Lupin receives EIR from USFDA for Nagpur Unit-1 manufacturing facility

29 Sep 2023 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Nagpur Unit-1 manufacturing facility that manufactures oral solid dosage forms. The EIR was issued post the last inspection of the facility conducted in July 2023. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2078.20 -27.65 (-1.31%)
05-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1730.15
Dr. Reddys Lab 1248.75
Cipla 1519.30
Zydus Lifesciences 921.80
Lupin 2078.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×